Ann Arbor-based Aastrom Biosciences is launching another Phase 2 clinical trial to study the effectiveness of its cell treatment for a disease that causes chronic heart failure. The clinical trial will examine whether Aastrom’s cardiac repair cell technology, delivered through a catheter, can treat dilated cardiomyopathy (DCM). The trial will ...
Rise: Timothy Mayleben The former CFO of Esperion Therapeutics - one of the most influential bioscience companies in Ann Arbor’s history - will take over as CEO of Aastrom Biosciences by the end of the year. Aastrom has suffered financial and regulator setbacks, but will now focus on cardiovascular drug ...
A life sciences executive who played a key role in the development of local biotech success Esperion Therapeutics is assuming the top job at an Ann Arbor personalized medicine company, officials announced today. Timothy Mayleben, a founding member of Esperion, will become chief executive officer of Aastrom Biosciences when CEO ...
Angela J. Cesere | AnnArbor.com AnnArbor.com's partner news site MLive.com is on a quest to find the best barbecue in ......
Get the Ann Arbor RSS Feed
AnnArbor.com